肿瘤分子靶向治疗临床应用值得注意的几个问题

Molecular targeted therapy for cancer:some points should be paid attention to

近年来,肿瘤分子靶向治疗临床应用方兴未艾。与传统的化疗细胞毒药物不同,肿瘤分子靶向药物不直接杀伤细胞,而是作用于肿瘤细胞过表达或突变、且与肿瘤恶性生物学行为密切相关的分子（靶点）,从而抑制肿瘤的过度增殖、新生血管生成、浸润和转移。然而,这类药物是不是就没有任何毒副作用,而可以放心大胆、不加选择地应用呢？临床应用应该注意些什么呢？现就我们临床应用此类药物的粗浅体会,提出对上述问题的若干思考,供同道们讨论、指正。

With the development of the genetics and molecular biology,great change is currently taking place in the treatment of cancer.Molecular targeted therapy is a new designed method and becomes more and more widely used.But the specificity and efficacy of this therapy is not very clear.In this way,identifying predictive biomarkers for resistance or sensitivity to these therapies is of great importance.Moreover,the side reaction of molecular targeted therapy is another noteworthy problem.In spite of these,molecular targeted therapy remains the new trend of future cancer therapy with a great development potential.